MilliporeSigma, the Life Science business of Merck KGaA in the U.S. and Canada, has announced a definitive agreement to acquire HUB Organoids Holding B.V. (HUB). This acquisition marks a significant step forward in enhancing their 2D and 3D cell culture portfolio with the innovative technology of
A groundbreaking study led by Natasha Chang at McGill University has shown that a novel drug, K884, holds promise for treating Duchenne muscular dystrophy (DMD), a devastating genetic disorder characterized by severe muscle degeneration. Unlike conventional treatments, which primarily focus on
The recent endorsement of Neuraxpharm's ublituximab (BRIUMVI®) by the National Institute for Health and Care Excellence (NICE) marks a significant step forward in the treatment of relapsing-remitting multiple sclerosis (RRMS). This approval is a notable accomplishment for the European
AbbVie's recent acquisition of Nimble Therapeutics, a Roche spinout specializing in peptide-based oral drugs for immune diseases, represents a strategic move to enhance its already robust immunology pipeline. The $200 million deal is aimed at bolstering AbbVie's portfolio, particularly
The Keck School of Medicine of USC has embarked on a groundbreaking research initiative aimed at addressing age-related cognitive decline in women. This significant effort is led by Dr. Young-Kwon Hong and has been bolstered by securing a $3.4 million federal grant from the Advanced Research
The field of drug discovery has long been hindered by the slow and laborious process of synthesizing and screening small molecules, putting a strain on scientific research advancements. Traditional methods are often time-consuming and require a high degree of specificity, making it difficult to
